DELTA 1: A Global, Multicenter, Phase 2 Study of ITIL-168, an Unrestricted Autologous Tumor-Infiltrating Lymphocyte Cell Therapy, in Adult Patients With Advanced Cutaneous Melanoma (SITC) Post date November 15, 2021 ← Potent T-Cell Costimulation Mediated by a Novel Costimulatory Antigen Receptor (CoStAR) With Dual CD28/CD40 Signaling Domains to Improve Adoptive Cell Therapies (SITC) → Costimulatory Antigen Receptor (CoStAR): A Novel Platform That Enhances the Activity of Tumor-Infiltrating Lymphocytes (SITC)
Instil Bio